Search Results 1761-1770 of 16381 for Chronic Lymphocytic Leukemia

1. An Open-label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma - Mayo Clinic

   ... CLL) may be enrolled. Patients with DLBCL transformation from prior CLL can only be enrolled in the absence of a leukemic CLL component. For patients with ...

2. Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma - Mayo Clinic

   Phase 4 trials look at long-term ... Patients with WM without lymphadenopathy must have > 10% lymphocytes ... Cardiac arrhythmias, including severe uncontrolled ...

3. Sumera I. Ilyas, M.B.B.S. - Mayo Clinic Faculty Profiles

   Her research team employs immunocompetent models of primary and metastatic liver cancer to study mechanisms of tumor immune evasion. The long-term goal of Dr.

4. Overview - Infectious Diseases Lab - Mayo Clinic Research

   Infectious Diseases Laboratory of Robin Patel, M.D., at Mayo Clinic: In vitro & in vivo investigation of antibacterial therapies & antibacterial resistance.

5. A Study to Examine Concussion Diagnosis in High School and Junior A Hockey Players - Mayo Clinic

   About this study. Concussion is a health issue impacting all athletes for which a clinical treatment protocol, other than rest, has not been established.

6. A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas - Mayo Clinic

   Diagnosis of lymphoblastic lymphoma. Eligibility last updated 8/12/21. Questions regarding updates should be directed to the study team contact ...

7. A Study Using VE303 to Prevent Recurrence of Clostridium Difficile Infection - Mayo Clinic

   History of acute leukemia or hematopoietic stem cell transplantation or myelosuppressive chemotherapy within 2 months prior to randomization. Subjects with ...

8. As blood cancer treatments evolve, so does the patient journey - Mayo Clinic News Network

   Editor's Note: September is Leukemia and Lymphoma Awareness Month. ROCHESTER, Minn. — Treatment for blood cancers is advancing, giving more options to ...

9. Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis - Mayo Clinic

   Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis · Overview · Participation eligibility · Participating Mayo ...

10. Primary Immunodeficiency Center in Minnesota - Overview - Mayo Clinic

    The Mayo Clinic Primary Immunodeficiency Center provides comprehensive care, including diagnosis and treatment, for people throughout the full age spectrum ...